

CORDLIFE GROUP LIMITED

(Company registration number: 200102883E)

(Incorporated in the Republic of Singapore)

RESPONSE TO SGX-ST QUERIES IN RELATION TO ANNOUNCEMENT

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**") refers to its announcement dated 2 October 2020 titled "Notification of Director's Assistance with Investigations in New Silkroutes Group Limited" ("**2 October Announcement**"). The Board wishes to inform that the Company has received a query from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") in relation to the 2 October Announcement and the Company's response to the query is as set out below.

Unless otherwise defined, all capitalised terms in the Company's response shall have the same meanings as are accorded to them in the 2 October Announcement.

Query from SGX-ST:

We refer to Cordlife Group Limited's (the "Company") 2 October 2020 announcement regarding the notification of a Director's assistance with investigations in New Silkroutes Group Limited ("NSG"). It was disclosed that "the Board understands that Dr Goh Jin Hian, Chairman and Independent Director of the Company who is concurrently the Non-Executive Chairman of NSG, and certain current and former management of NSG, are assisting with investigations conducted by the Commercial Affairs Department ("CAD") into a possible offence under the Securities and Futures Act (Chapter 289 of Singapore) in relation to NSG (the "CAD Investigations")."

Listing Rule 720(1) of the Listing Manual provides that an issuer must also comply with Listing Rule 210(5) on a continuing bases, which requires among others, a consideration of the character and integrity of directors and management. Please provide the Board and Nominating Committee's assessment and the bases for such assessment of whether Dr Goh Jin Hian is suitable to remain as the Chairman and Independent Director of the Company.

Company's Response:

The Board had understood from the NSG Announcement that Dr Goh has been asked to assist with the ongoing CAD Investigations, and while Dr Goh's passport has been retained by the CAD, no arrests or charges have been made and no bail has been required to be posted for any persons that are assisting with the CAD Investigations. Based on the NC and the Board's interactions with Dr Goh, the NC and the Board is of the view that Dr Goh has always displayed a high level of professionalism, integrity and strong leadership in his conduct during Board discussions and meetings, and that the Company has benefited from Dr Goh's strong guidance and leadership in his years of service on the Board.

In view of the foregoing, the NC had assessed the situation based on the information available to the Company as at the 2 October Announcement, and had formed the view that there is nothing at this juncture to indicate that Dr Goh's ability to oversee and manage the affairs of the Company as Chairman and Independent Director of the Company ("ID") would be compromised as a result of the ongoing CAD Investigations, and that it would be in the best interests of the Company for Dr Goh to presently continue with his roles and responsibilities as Chairman and ID. The Board (with Dr Goh abstaining) has accepted the NC's recommendation and is supportive of his continued service on the Board as Chairman and ID.

As stated in the 2 October Announcement, the NC and the Board will continue to evaluate the suitability of Dr Goh's service on the Board based on the progress of the CAD Investigations, and will make the relevant announcements as and when appropriate, in compliance with the listing rules of the SGX-ST.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Tan Poh Lan
Executive Director and Group CEO
05 October 2020